![]() | Up a level |
Zelniker, Thomas A, Raz, Itamar, Mosenzon, Ofri, Dwyer, Jamie P, Heerspink, Hiddo HJL, Cahn, Avivit, Goodrich, Erica L, Im, Kyungah, Bhatt, Deepak L, Leiter, Lawrence A et al (show 6 more authors)
(2021)
Effect of Dapagliflozin on Cardiovascular Outcomes According to Baseline Kidney Function and Albuminuria Status in Patients With Type 2 Diabetes: A Prespecified Secondary Analysis of a Randomized Clinical Trial.
JAMA Cardiology, 6 (7).
pp. 801-810.
Zelniker, Thomas A, Wiviott, Stephen D, Raz, Itamar, Im, Kyungah, Goodrich, Erica L, Bonaca, Marc P, Mosenzon, Ofri, Kato, Eri T, Cahn, Avivit, Furtado, Remo HM et al (show 5 more authors)
(2019)
SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials.
LANCET, 393 (10166).
pp. 31-39.